Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
In mild to moderate disease : 300 mg to 600 mg daily by slow intramuscular or intravenous injection
Divinski I, Mittelman L, Gozes I
Answer : The major players in the GLP-1 analogues market include Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Pfizer, Amgen, Roche, Zealand Pharma, Structure Therapeutics, Viking Therapeutics, Hangzhou Sciwind Biosciences, Fudan University, Eccogene, Medtronic, Merck & Co., AbbVie, Bayer AG, Teva Pharmaceutical Industries Ltd., and Boehringer Ingelheim
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to manage type 2 diabetes and, more recently, for chronic weight management in adults with obesity or overweight with weight-related comorbidities
US$ 25.86
US$ 23.64
US$ 26.64
US$ 21.44
US$ 27.75
US$ 22.52
US$ 28.86
US$ 27.35
